POXEL — Poxel SA Share News
0.000.00%
Last trade - 00:00- €9.32m
- €68.25m
- €6.64m
Brief: Poxel Initiates Phase 2 NASH Trial For PXL065
Brief: Poxel Announces Submission Of Imeglimin Japanese New Drug Application
Brief: Poxel H1 Revenue Down At 6.4 Million Euros
Brief: Poxel Announces Positive Pharmacokinetic/Pharmacodynamic Study Results For Pxl770
Brief: Poxel: PXL770 PK/PD And Phase 2a Studies In Nash Remain On Track For Results In Q2 And Q3
Brief: Poxel End-March Cash And Cash Equivalents Down At 36.9 Million Euros
Brief: Poxel Announces Publication Of Imeglimin Clinical Study Results
Brief: Poxel FY Net Result Turns To Loss Of 25.8 Million Euros
Brief: Poxel FY Revenue Down At 26.6 million Euros
Brief: Poxel Presents New Preclinical Results For PXL770
Brief: Rpt-Poxel SA - Times 2 Was Third And Final Pivotal Registration Trial From Phase 3 Times Program
Brief: Poxel Announces Positive Results For PXL065 Phase 1B Trial
Brief: Poxel Announces Positive Topline Results For Imeglimin Phase 3 Trial (TIMES 3 36-Week)
Brief: Poxel Announces Favorable PXL065 Phase 1a Trial Results
Brief: Poxel Announces Positive Update Following FDA Meeting For PXL065 For Treatment Of NASH
Brief: Poxel Issues Bonds For Up To EUR 30 Mln, Sees Clinical Trial Results In Q4
Brief: Poxel Q3 Revenue Down At EUR 2.8 Mln
Brief: Poxel Announces Detailed Imeglimin Phase 3 TIMES 1 Results
Brief: Poxel Initiates Phase 1B MAD Trial For Nash Drug Candidate